Our investigational therapy is a novel ocular regenerative gene therapy product that is delivered one-time into the eye with an intraocular injection. This therapy makes retinal cells more resistant to stress, helps cells repair damage, and increases their lifespan. It has the potential to activate dormant stem cells in the retina to replace lost tissue. Its benefit has been demonstrated in preclinical research, and the company is completing its preclinical research program to prepare for entry into Phase 1 clinical trials.